A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer’s Disease in the US and Finland

Drugs and Aging

Volumn 34, Issue 1, 2017, Pages 55-65

  Moga, Daniela C ^a,b,c   Taipale, Heidi ^d,e   Tolppanen, Anna Maija ^d   Tanskanen, Antti ^d,e   Tiihonen, Jari ^d,e   Hartikainen, Sirpa ^d,f   Wu, Qishan ^b   Jicha, Gregory A ^c   Gnjidic, Danijela ^g  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e KAROLINSKA INSTITUTE   (Sweden)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINESTERASE INHIBITOR; HYPNOTIC AGENT; MEMANTINE; NEUROLEPTIC AGENT; NOOTROPIC AGENT; SEDATIVE AGENT; HYPNOTIC SEDATIVE AGENT; PSYCHOTROPIC AGENT;

ADULT; AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANXIETY; ARTICLE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; DELUSION; DEMOGRAPHY; DEPRESSION; DRUG USE; DRUG UTILIZATION; DYSPHORIA; FEMALE; FINLAND; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SOCIAL STATUS; UNITED STATES; EPIDEMIOLOGY; MIDDLE AGED; ODDS RATIO; PREVALENCE; PSYCHOLOGY; SEXUAL DEVELOPMENT; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DRUG UTILIZATION; FEMALE; FINLAND; HUMANS; HYPNOTICS AND SEDATIVES; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; PSYCHOTROPIC DRUGS; SEX CHARACTERISTICS; UNITED STATES;

EID: 84997706057     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-016-0419-5     Document Type: Article

References (48)

1. Rattinger GB, et al. Pharmacotherapeutic management of dementia across settings of care. J Am Geriatr Soc. 2013;61(5):723–33.
2. Gnjidic D, et al. Impact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer’s disease: a national population cohort study. PLoS One. 2014;9(1):e83224.
3. Vasudev A, et al. Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004–2013. Am J Geriatr Psychiatry. 2015;23(12):1259–69.
4. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD003476.
5. Banerjee S, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):403–11.
6. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.
7. Gnjidic D, et al. Drug Burden Index associated with function in community dwelling older people living in Finland: a cross-sectional study. Ann Med. 2012;44:458–67.
8. Gnjidic D, et al. High risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91:521–8.
9. Legato MJ, Johnson PA, Manson JE. Consideration of sex differences in medicine to improve health care and patient outcomes. JAMA. 2016;316(18):1865–6.
10. Clayton JA, Tannenbaum C. Reporting sex, gender, or both in clinical research? JAMA. 2016;316(18):1863–4.
11. Bierman AS, et al. Sex differences in inappropriate prescribing among elderly veterans. Am J Geriatr Pharmacother. 2007;5(2):147–61.
12. Johnell K, Weitoft GR, Fastbom J. Sex differences in inappropriate drug use: a register-based study of over 600,000 older people. Ann Pharmacother. 2009;43(7):1233–8.
13. Foebel AD, et al. Quality of care in European home care programs using the second generation interRAI Home Care Quality Indicators (HCQIs). BMC Geriatr. 2015;15(1):148.
14. Lovheim H, et al. Sex differences in the prevalence of behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2009;21(3):469–75.
15. Zuidema SU, et al. Predictors of neuropsychiatric symptoms in nursing home patients: influence of gender and dementia severity. Int J Geriatr Psychiatry. 2009;24(10):1079–86.
16. Taipale H, et al. Antipsychotic doses among community-dwelling persons with Alzheimer disease in Finland. J Clin Psychopharmacol. 2014;34(4):435–40.
17. Rochon PA, et al. Older men with dementia are at greater risk than women of serious events after initiating antipsychotic therapy. J Am Geriatr Soc. 2013;61(1):55–61.
18. Lucas C, Byles J, Martin JH. Medicines optimisation in older people: taking age and sex into account. Maturitas. 2016;93:114–20.
19. Beekly DL, et al. The National Alzheimer’s Coordinating Center (NACC) database: the uniform data set. Alzheimer Dis Assoc Disord. 2007;21(3):249–58.
20. Beekly DL, et al. The National Alzheimer’s Coordinating Center (NACC) database: an Alzheimer disease database. Alzheimer Dis Assoc Disord. 2004;18(4):270–7.
21. Morris JC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20(4):210–6.
22. Weintraub S, et al. The Alzheimer’s Disease Centers’ Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009;23(2):91–101.
23. McKhann G, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–44.
24. WHO Collobarating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical classification system: structure and principles. 2015. http://www.whocc.no/atc/structure_and_principles/. Accessed 15 Nov 2016.
25. Taipale H, et al. High prevalence of psychotropic drug use among persons with and without Alzheimer’s disease in Finnish nationwide cohort. Eur Neuropsychopharmacol. 2014;24(11):1729–37.
26. Taipale H, et al. Antipsychotic polypharmacy among a nationwide sample of community-dwelling persons with Alzheimer’s disease. J Alzheimers Dis. 2014;41(4):1223–8.
27. Taipale H, et al. Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study. Int Clin Psychopharmacol. 2014;29(4):216–23.
28. Tolppanen AM, et al. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research. The Medication use among persons with Alzheimer’s Disease (MEDALZ-2005) study. Clin Epidemiol. 2013;5:277–85.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
30. Duodecim FMS. Current care: memory disorders [in Finnish with English summary]. 2010. http:\\www.kaypahoito.fi. Accessed 15 Nov 2016.
31. Taipale H, et al. Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer’s disease. Int Clin Psychopharmacol. 2015;30(4):202–8.
32. Taipale H, et al. Hospital care and drug costs from five years before until two years after the diagnosis of Alzheimer’s disease in a Finnish nationwide cohort. Scand J Public Health. 2016;44(2):150–8.
33. Tanskanen A, et al. From prescription drug purchases to drug use periods: a second generation method (PRE2DUP). BMC Med Inform Decis Mak. 2015;15:21.
34. Galobardes B, et al. Indicators of socioeconomic position (part 1). J Epidemiol Commun Health. 2006;60(1):7–12.
35. Galobardes B, et al. Indicators of socioeconomic position (part 2). J Epidemiol Commun Health. 2006;60(2):95–101.
36. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.
37. Folstein MF, Folstein SE, McHugh PR. ”Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
38. Cummings JL, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–14.
39. Kaufer DI, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12(2):233–9.
40. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol. 1986;5(1/2):65–173.
41. SAS Institute Inc. SAS version 9.4. Cary: SAS Institute Inc.; 2013.
42. Paulose-Ram R, et al. Trends in psychotropic medication use among U.S. adults. Pharmacoepidemiol Drug Saf. 2007;16(5):560–70.
43. Morgan SG, et al. Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults. Age Ageing. 2016;45(4):535–42.
44. Petrovic M, et al. Personality traits and socio-epidemiological status of hospitalised elderly benzodiazepine users. Int J Geriatr Psychiatry. 2002;17(8):733–8.
45. Kitamura T, et al. Gender differences in clinical manifestations and outcomes among hospitalized patients with behavioral and psychological symptoms of dementia. J Clin Psychiatry. 2012;73(12):1548–54.
46. Steinberg M, et al. Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2006;21(9):824–30.
47. Kales HC, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry. 2011;68(2):190–7.
48. Dutcher SK, et al. Effect of medications on physical function and cognition in nursing home residents with dementia. J Am Geriatr Soc. 2014;62(6):1046–55.